Establishment Labs Holdings Inc
NASDAQ:ESTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (32.2), the stock would be worth $25.91 (60% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 80.1 | $64.4 |
0%
|
| 3-Year Average | 32.2 | $25.91 |
-60%
|
| 5-Year Average | 30.4 | $24.42 |
-62%
|
| Industry Average | 119.9 | $96.32 |
+50%
|
| Country Average | 119.9 | $96.32 |
+50%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CR |
|
Establishment Labs Holdings Inc
NASDAQ:ESTA
|
1.9B USD | 80.1 | -37 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.9T JPY | 9.6 | 39.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.1B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
29B CHF | 1.6 | 36.4 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
92B DKK | 6.6 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 3.1 | 30.9 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 3.6 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
39.1B CNY | 4.5 | 23.7 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
905.8B JPY | 5.7 | 51.2 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | 19.9 | -37.8 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 0.9 | -15.3 |
Market Distribution
| Min | 119.9 |
| 30th Percentile | 119.9 |
| Median | 119.9 |
| 70th Percentile | 119.9 |
| Max | 119.9 |
Other Multiples
Establishment Labs Holdings Inc
Glance View
Established at the intersection of innovation and aesthetics, Establishment Labs Holdings Inc. has carved a niche in the global medical technology landscape. Founded in 2004, this Costa Rica-based company has painstakingly built a reputation for its cutting-edge silicone breast implants and medical devices aimed at breast aesthetics and reconstruction. The company leverages advanced technology to deliver safer and more natural products, primarily through its signature Motiva Implants® brand. With its commitment to safety, quality, and innovation, Establishment Labs has successfully expanded into more than 80 countries, earning trust by catering to surgeons and patients with an ever-evolving portfolio of aesthetically driven solutions. Establishment Labs’ business model is intricately tied to the nuances of the cosmetic surgery industry, where product differentiation and regulatory compliance are paramount. The company invests heavily in research and development, focusing on creating next-generation breast implant technologies that prioritize patient safety and satisfaction. Revenue streams are driven by direct sales to plastic surgeons and healthcare providers, capitalizing on growing global demand for aesthetic procedures. Additionally, the company stays ahead of the competition by fostering strong relationships with medical professionals and continuously educating them about the benefits and capabilities of its innovative product offerings. This strategic alliance strengthens its market presence and aids consistent revenue growth, reinforcing its status as a forward-thinking leader in the medical aesthetics field.